Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Other share classesJSPRW
Q2 2026 vs. Q1 2026
How the institutions holding Jasper Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 58 | 45 | −13 |
| Shares | 15.8M | 12.0M | −3.81M (−24.1%) |
| Value | $13.9M | $5.05M | −$8.81M (−63.6%) |
New holders (3)
Institutions that held Jasper Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Qube Research & Technologies Ltd | 33,722 | $14.2K | 0.00% |
| SG Americas Securities, LLC | 10,556 | $4.00K | 0.00% |
| SRS Capital Advisors, Inc. | 573 | $241 | 0.00% |
Sold out (16)
Institutions that held Jasper Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Boothbay Fund Management, LLC | 582,751 | $510.6K |
| Jacobs Levy Equity Management, Inc | 322,273 | $282.4K |
| Soleus Capital Management, L.P. | 276,312 | $242.1K |
| Knott David M Jr | 160,789 | $140.9K |
| Verdad Advisers, LP | 73,967 | $64.8K |
| Squarepoint Ops LLC | 64,915 | $56.9K |
| Marshall Wace, LLP | 45,656 | $40.2K |
| Nine Masts Capital Ltd | 44,165 | $38.7K |
| Readystate Asset Management LP | 27,499 | $24.1K |
| Panagora Asset Management Inc | 21,543 | $18.9K |
| Dimensional Fund Advisors LP | 18,664 | $16.4K |
| Susquehanna International Group, LLP | 11,149 | $9.77K |
| Vanguard Global Advisers, LLC | 3,972 | $3.48K |
| US Bancorp | 500 | $438 |
| Wells Fargo & Company | 500 | $438 |
| Optiver Holding B.V. | 7 | $6 |